Show simple item record

dc.contributor.authorCruz-Tapias, Paola
dc.contributor.authorZakharova, Vlada
dc.contributor.authorPerez-Fernandez, Oscar M.
dc.contributor.authorMantilla, William
dc.contributor.authorRamírez-Clavijo, Sandra
dc.contributor.authorAit-Si-Ali, Slimane
dc.date.accessioned2021-06-23T18:02:45Z
dc.date.available2021-06-23T18:02:45Z
dc.date.issued2019-08-08
dc.identifier.issn2072-6694spa
dc.identifier.urihttp://hdl.handle.net/20.500.12495/5899
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherMDPIspa
dc.relation.ispartofseriesCancers, 2072-6694, Vol. 11, No. 08, 2019, Art. 1134spa
dc.relation.urihttps://www.mdpi.com/2072-6694/11/8/1134spa
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleExpression of the major and pro-Oncogenic H3K9 lysine methyltransferase SETDB1 in non-Small cell lung cancerspa
dc.type.localArtículo de revista
dc.subject.keywordsSETDB1/KMT1Espa
dc.subject.keywordsLysine methyltransferasespa
dc.subject.keywordsNon-small cell lung cancerspa
dc.subject.keywordsMeta-analysisspa
dc.identifier.doihttps://doi.org/10.3390/cancers11081134spa
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.publisher.journalCancersspa
dc.type.coarhttp://purl.org/coar/resource_type/c_6501
dc.type.driverinfo:eu-repo/semantics/article
dc.identifier.instnameinstname:Universidad El Bosque
dc.identifier.reponamereponame:Repositorio Institucional Universidad El Bosque
dc.identifier.repourlrepourl:https://repositorio.unbosque.edu.co
dc.title.translatedExpression of the major and pro-Oncogenic H3K9 lysine methyltransferase SETDB1 in non-Small cell lung cancerspa
dc.description.abstractenglishSETDB1 is a key histone lysine methyltransferase involved in gene silencing. The SETDB1 gene is amplified in human lung cancer, where the protein plays a driver role. Here, we investigated the clinical significance of SETDB1 expression in the two major forms of human non-small cell lung carcinoma (NSCLC), i.e., adenocarcinoma (ADC) and squamous cell carcinoma (SCC), by combining a meta-analysis of transcriptomic datasets and a systematic review of the literature. A total of 1140 NSCLC patients and 952 controls were included in the association analyses. Our data revealed higher levels of SETDB1 mRNA in ADC (standardized mean difference, SMD: 0.88; 95% confidence interval, CI: 0.73–1.02; p < 0.001) and SCC (SMD: 0.40; 95% CI: 0.13–0.66; p = 0.003) compared to non-cancerous tissues. For clinicopathological analyses, 2533 ADC and 903 SCC patients were included. Interestingly, SETDB1 mRNA level was increased in NSCLC patients who were current smokers compared to non-smokers (SMD: 0.26; 95% CI: 0.08–0.44; p = 0.004), and when comparing former smokers and non-smokers (p = 0.009). Furthermore, the area under the curve (AUC) given by the summary receiver operator characteristic curve (sROC) was 0.774 (Q = 0.713). Together, our findings suggest a strong foundation for further research to evaluate SETDB1 as a diagnostic biomarker and/or its potential use as a therapeutic target in NSCLC.spa
dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf2
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.accessrightsAcceso abiertospa


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
Except where otherwise noted, this item's license is described as Atribución 4.0 Internacional